case_images: PMC10601716_01
case_images: SPEARHEAD-1 Trial Design (SPEARHEAD-1 study in subjects with advanced synovial Sarcoma or myxoid/round cell liposarcoma, NCT04044768).
case_images: cro-2023-0016-0001-533129_F02.jpg
case_images: PMC10601716_01_cro-2023-0016-0001-533129_F02.jpg
case_images: F2
case_images: HLAx02 and MAGE-A4 positive participants in this trial undergo leukapheresis, and their isolated T-cells are transduced with the MAGE-A4 T-cell receptor and expanded (Fig. 2).
case_images: Adrenal glands before and after completion of rituximab. (Left - March 2022, right - June 2022). Top images highlight the metabolic resolution of right adrenal nodule, and bottom images highlight the decrease of left adrenal nodule. Arrows highlight hypermetabolic adrenal nodules. a Right adrenal nodule in March 2022. b Right adrenal nodule in June 2022. c Left adrenal nodule in March 2022. d Left adrenal nodule in June 2022.
case_images: cro-2023-0016-0001-533129_F03.jpg
case_images: PMC10601716_01_cro-2023-0016-0001-533129_F03.jpg
case_images: F3
case_images: PET scan in June showed resolution of lymphoproliferative disease to treatment with metabolic resolution of the right adrenal lesion and decreased size and metabolic uptake of the left adrenal lesion (Fig. 3).